Related Experiment Videos

Potent antimyeloma activity of a novel ERK5/CDK inhibitor

Stela Álvarez-Fernández1, María Jesús Ortiz-Ruiz, Tracy Parrott

  • 1Instituto de Biología Molecular y Celular del Cáncer, CSIC-IBSAL-Universidad de Salamanca, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 28, 2013
PubMed
Abstract

Insights

TG02, an ERK5/CDK inhibitor, shows potent antimyeloma activity by inducing apoptosis and cell-cycle arrest in multiple myeloma cells. This drug is a promising agent currently in clinical trials.

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
  • Therapeutic options for multiple myeloma are limited, necessitating the development of novel agents.
  • Understanding the molecular mechanisms underlying multiple myeloma pathogenesis is crucial for targeted therapy.

Purpose of the Study:

  • To evaluate the antimyeloma potential of TG02, a novel drug targeting ERK5 and cyclin-dependent kinases (CDKs).
  • To investigate the mechanism of action of TG02 in multiple myeloma cells and patient samples.
  • To assess the efficacy of TG02 as a single agent and in combination with existing therapies in preclinical models.

Main Methods:

  • MTT assays were used to determine the effect of TG02 on multiple myeloma cell viability.
  • Flow cytometry was employed to analyze apoptosis, cell cycle, and mitochondrial membrane potential.
  • Western blotting was utilized to investigate the drug's impact on key signaling proteins.
  • In vivo efficacy was assessed using two multiple myeloma xenograft models.

Main Results:

  • TG02 demonstrated potent inhibition of multiple myeloma cell proliferation and survival, including under protective bone marrow niche conditions.
  • The drug selectively induced apoptosis in primary patient-derived malignant plasma cells.
  • TG02 exhibited significant single-agent activity in vivo and enhanced the efficacy of bortezomib and lenalidomide.
  • Mechanism of action studies revealed TG02 simultaneously inhibited CDKs and ERK5, leading to cell-cycle arrest, apoptosis, and depletion of survival proteins like Mcl-1.

Conclusions:

  • TG02 is a promising novel agent with significant antimyeloma activity.
  • The drug's ability to induce apoptosis and cell-cycle arrest makes it a potential therapeutic candidate.
  • TG02 is currently undergoing Phase I clinical trials for leukemia and multiple myeloma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...